Jesús
San Miguel Izquierdo
Consultor Investigador
Kiel University
Kiel, AlemaniaKiel University-ko ikertzaileekin lankidetzan egindako argitalpenak (6)
2016
-
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515
2015
-
Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers
Genome Research, Vol. 25, Núm. 4, pp. 478-487
2014
2013
-
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma
Journal of Clinical Oncology
2011
-
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
Blood, Vol. 118, Núm. 17, pp. 4519-4529
2009
-
Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA